Key result
ANGPTL4 inactivates lipoprotein lipase by directly catalyzing the unfolding of LPL monomers, demonstrating that inactivation does not require the conversion of LPL homodimers into monomers.
Why the study?
Existing dogma held that ANGPTL proteins inactivate lipoprotein lipase by converting homodimers into monomers that spontaneously unfold, but the precise mechanism of inactivation remained to be clarified.
This basic science study challenges long-standing dogma by demonstrating that ANGPTL4 inactivates lipoprotein lipase by catalyzing its unfolding, a process that does not require prior conversion of LPL homodimers into monomers.
Challenges established LPL regulation models; extends mechanistic insights but leaves therapeutic translation in dyslipidemia unresolved.
The binding of lipoprotein lipase (LPL) to GPIHBP1 focuses the intravascular hydrolysis of triglyceride-rich lipoproteins on the surface of capillary endothelial cells. This process provides essential lipid nutrients for vital tissues (e.g., heart, skeletal muscle, and adipose tissue). Deficiencies in either LPL or GPIHBP1 impair triglyceride hydrolysis, resulting in severe hypertriglyceridemia. The activity of LPL in tissues is regulated by angiopoietin-like proteins 3, 4, and 8 (ANGPTL). Dogma has held that these ANGPTLs inactivate LPL by converting LPL homodimers into monomers, rendering them highly susceptible to spontaneous unfolding and loss of enzymatic activity. Here, we show that binding of an LPL-specific monoclonal antibody (5D2) to the tryptophan-rich lipid-binding loop in the carboxyl terminus of LPL prevents homodimer formation and forces LPL into a monomeric state. Of note, 5D2-bound LPL monomers are as stable as LPL homodimers (i.e., they are not more prone to unfolding), but they remain highly susceptible to ANGPTL4-catalyzed unfolding and inactivation. Binding of GPIHBP1 to LPL alone or to 5D2-bound LPL counteracts ANGPTL4-mediated unfolding of LPL. In conclusion, ANGPTL4-mediated inactivation of LPL, accomplished by catalyzing the unfolding of LPL, does not require the conversion of LPL homodimers into monomers. Thus, our findings necessitate changes to long-standing dogma on mechanisms for LPL inactivation by ANGPTL proteins. At the same time, our findings align well with insights into LPL function from the recent crystal structure of the LPL•GPIHBP1 complex.
No takes yet. Share an insight, caveat, or question.
Kristensen et al. (2020) studied Plasma triglyceride metabolism. ANGPTL4 was evaluated on Unfolding of LPL monomers. ANGPTL4 inactivates lipoprotein lipase by directly catalyzing the unfolding of LPL monomers, demonstrating that inactivation does not require the conversion of LPL homodimers into monomers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: